Literature DB >> 23617083

Vitiliginous lesions induced by amyl nitrite exposure.

Kathleen Vine1, Marc Meulener, Sherry Shieh, Nanette B Silverberg.   

Abstract

Chemical (or contact) leukoderma is a condition induced by local cutaneous exposure to chemicals or medicaments that are toxic to melanocytes and/or koebnerize preexisting vitiligo vulgaris. Chemicals known to induce leukoderma include phenol/catechol derivatives (eg, hydroquinone), sulfhydryls, contact sensitizing agents (eg, squaric acid dibutylester), and more recently imiquimod, among others. We report the case of a 37-year-old black man with human immunodeficiency virus who developed chemical leukoderma in the nasal and perioral areas within 4 weeks of spilling liquid amyl nitrite, which he had been inhaling as a recreational drug, on his lower face. The depigmented regions were treated with a biweekly regimen of 308-nm excimer laser treatment for a total of 78 sessions. More than 90% cutaneous repigmentation was achieved. Amyl nitrite-induced vitiliginous lesions are rare. We also discuss potential mechanisms of hypopigmentation from chemical agents and therapeutic options for chemical leukoderma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23617083

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  4 in total

Review 1.  Dermatologic care for lesbian, gay, bisexual, and transgender persons: Epidemiology, screening, and disease prevention.

Authors:  Howa Yeung; Kevin M Luk; Suephy C Chen; Brian A Ginsberg; Kenneth A Katz
Journal:  J Am Acad Dermatol       Date:  2019-03       Impact factor: 11.527

Review 2.  308nm excimer laser in dermatology.

Authors:  Shadi Mehraban; Amir Feily
Journal:  J Lasers Med Sci       Date:  2014

3.  Thymol-Induced Chemical Leukoderma Successfully Treated with 308-Nanometer Excimer Laser.

Authors:  Maximillian A Weigelt; Alexander T Herbst; Antonella Tosti; Hadar Lev-Tov
Journal:  Skin Appendage Disord       Date:  2020-06-02

4.  Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response.

Authors:  Qianli Yang; Guohong Zhang; Mingwan Su; Gigi Leung; Harvey Lui; Pingyu Zhou; Yan Wu; Joshua Zhou; Jinhua Xu; Xuejun Zhang; Youwen Zhou
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.